Thomas Rohrer, Head of Antibody Drug Conjugation Project Evaluation at Lonza, has 30 years of experience in development, scale-up and manufacturing. He established process development and clinical manufacturing of ADC(s) at Cambrex Biopharma in 2004.
After Cambrex Biopharma was acquired by Lonza in 2007 Rohrer joined the Lonza Exclusive Synthesis ADC business team in Visp, Switzerland to help establish ADC manufacturing.
Prior to joining Lonza he held senior positions in biotherapeutics process development and manufacturing at Human Genome Sciences, Otsuka Pharmaceutical and the National Cancer Institute (NCI) – Frederick Cancer Research Facility. He holds a B.S. in Biochemistry and M.S. in Chemical Engineering.
Lonza is a founding member of ADC Review / Journal of Antibody-drig Conjugates.
Last Editorial Review: March 15, 2015
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.